Moleculin Biotech (NASDAQ:MBRX) Lowered to “Strong Sell” Rating by Wall Street Zen

Wall Street Zen lowered shares of Moleculin Biotech (NASDAQ:MBRX) from a sell rating to a strong sell rating in a report issued on Saturday.

Other equities research analysts also recently issued reports about the stock. HC Wainwright restated a “buy” rating and issued a $22.00 price target on shares of Moleculin Biotech in a research note on Tuesday, March 24th. Weiss Ratings restated a “sell (e+)” rating on shares of Moleculin Biotech in a research note on Tuesday, April 21st. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $22.00.

Moleculin Biotech Stock Down 4.1%

Shares of Moleculin Biotech stock opened at $2.11 on Friday. The company has a market capitalization of $11.27 million, a price-to-earnings ratio of -0.06 and a beta of 1.74. Moleculin Biotech has a 12-month low of $1.79 and a 12-month high of $25.00. The firm’s 50-day moving average price is $2.33 and its two-hundred day moving average price is $4.72.

Moleculin Biotech (NASDAQ:MBRX) last announced its quarterly earnings data on Thursday, May 14th. The company reported ($3.54) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.33) by ($1.21). On average, sell-side analysts expect that Moleculin Biotech will post -4.89 earnings per share for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Moleculin Biotech stock. Jane Street Group LLC bought a new stake in shares of Moleculin Biotech, Inc. (NASDAQ:MBRX) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund bought 22,550 shares of the company’s stock, valued at approximately $75,000. Jane Street Group LLC owned 1.11% of Moleculin Biotech as of its most recent SEC filing. 15.52% of the stock is currently owned by hedge funds and other institutional investors.

Moleculin Biotech Company Profile

Moleculin Biotech, Inc is a clinical-stage pharmaceutical company focused on the development of novel therapies for the treatment of highly resistant tumors and viral infections. The company’s research platform centers on the design and synthesis of drug candidates that target key cellular pathways in cancer cells and viral replication processes. By leveraging a proprietary chemistry approach, Moleculin aims to address diseases that have limited therapeutic options and high unmet medical need.

The company’s pipeline includes multiple product candidates at various stages of development.